An overview of considerations for the testing of tamoxifen as a preventive for breast cancer.
Jordan
V C
VC
Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA.
D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D001943:Breast Neoplasms / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity
D016588:Anticarcinogenic Agents; D013629:Tamoxifen